HSPG2 and liver cancer: Ling Li et al. screened 129 anti-tumor drugs using patient-derived liver cancer organoids and found significant differences in the efficacy of clinically used drugs, such as sorafenib and gemcitabine, among patients with PLC (Li L. et al., 2019).